PARP inhibitors could exploit weaknesses in a range of cancers
Drug type could offer a new approach to treating a number of cancers with PBRM1 mutations
Read More
Tag: PARP inhibitor
New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
Talzenna bags EU approval for gBRCA-mutated breast cancer
The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
Read More
Lynparza use extended in EMA CHMP meeting
The positive opinion is based on data from the pivotal Phase III SOLO-1 trial.
Read More
EU filing for Clovis’ Rubraca in ovarian cancer maintenance setting
Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
New US approval for Clovis’ Rubraca
Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
Read More
EU reviews first PARP inhibitor for breast cancer
MSD and AstraZeneca’s Lynparza will be the first PARP inhibitor to be reviewed in Europe for the treatment of breast cancer, after the European Medicines Agency validated the drug’s marketing application in this setting.
Read More
AZ deepens ties with Myriad on Lynparza companion test
AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced ovarian cancer most likely to benefit from its medicines.
Read More
Researchers develop new test to target prostate cancer treatment
UK-based scientists have developed a new three-in-one blood test able to identify the patients with advanced prostate cancer most likely to benefit from PARP inhibitors, with the potential to ‘transform’ treatment of the disease.
Read More
AbbVie’s PARP inhibitor fails in PhIII trials
AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.
Read More
AstraZeneca’s Lynparza hits breast cancer trial targets
A late-stage study of AstraZeneca’s PARP inhibitor Lynparza in patients with HER2-negative metastatic breast cancer who also carry BRCA1 or BRCA2 mutations has its primary target of boosting progression-free survival (PFS).
Read More
Orphan status for AbbVie’s PARP inhibitor
AbbVie’s experimental lung cancer drug veliparib has picked up Orphan Drug status in the US, opening the door to potential tax credits, waived fees, protocol assistance and exclusivity benefits.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
